American Journal of Psychiatry

Article	Citations
Broadening the Parameters of Clinical High Risk for Psychosis	446
2024 Annual Meeting: Presidential Address	360
Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	190
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	172
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	133
Evaluating Associations Between Cannabis and Heroin Use	132
Treating Pathologies of the Will	121
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	120
Mental Health Disparities Research: An Introduction to New Directions	116
Highlights From the Residents’ Journal: December 2021	109
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	106
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	106
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	99
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	92
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	90
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	90
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	88
Depression, Inflammation, and Postpartum Psychosis	88
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	84
Intentional Drug Overdose Deaths in the United States	84
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide	84
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	80
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	79
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	78
New Insights Into Psychotic Disorders	78

2024 Annual Meeting: CEO and Medical Director’s Address	76
Correcting Overestimations in Self-Harm Visit Data	75
Highlights From the Residents’ Journal: September 2021	75
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	69
Highlights From the Residents’ Journal: September 2024	69
APA Council Reports	69
Correction to Poirot et al.	65
Corrigendum to Morley et al.	64
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	64
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	62
Suicide and the Menstrual Cycle	59
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	58
Whole Brain White Matter Tract Deviation and Idiosyncrasy From Normative Development in Autism and ADHD and Unaffected Siblings Link With Dimensions of Psychopathology and Cognition	57
Coordinate Network Mapping: An Emerging Approach for Morphometric Meta-Analysis	56
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	54
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	54
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	54
Early Adversity and Development: Parsing Heterogeneity and Identifying Pathways of Risk and Resilience	53
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	52
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	51
Familial Risk of Postpartum Psychosis	51
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	50
The First Large GWAS Meta-Analysis for Postpartum Depression	50
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	50
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	49
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	48
Risk of Incident Psychosis and Mania With Prescription Amphetamines	48
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	47
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	47
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	46
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	45
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	44
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	43
Insights Into Improving Clinical Outcomes Across Psychiatric Disorders and Medical Comorbidities	42
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	42
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	40
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	40
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	40
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	40
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	39
2021 Articles of Import and Impact	38
Alcohol and the Etiology of Depression	38
Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	37
Suicide in Black Females	37
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder	37
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	37
Psilocybin: From Psychiatric Pariah to Perceived Panacea	36
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	36
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	35
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	35

Modification of Heritability for Educational Attainment and Fluid Intelligence by Socioeconomic Deprivation in the UK Biobank	35
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	34
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	33
Evaluating the Machine Learning Literature: A Primer and User’s Guide for Psychiatrists	33
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	33
Cigarette Smoking and Heavy Alcohol Drinking: The Challenges and Opportunities for Combination Treatments	32
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment	32
Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	32
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	32
Neuromodulation Strategies for the Treatment of Depression	31
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	31
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	31
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	31
Changing the Face of Schizophrenia	31
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	31
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	30
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	30
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	30
Correction to Baum et al.	30
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	29
Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD	29
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	29
Structural Racism as a Proximal Cause for Race-Related Differences in Psychiatric Disorders	28
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	28
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	27
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	27
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	27
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	27
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	27
The Amygdala and Depression: A Sober Reconsideration	26
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	26
Innovative Directions to Advance Mental Health Disparities Research	26
Toward Precision Noninvasive Brain Stimulation	26
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	26
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review	26
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	25
2024 Articles of Import and Impact	25
Correction	25
Ketamine After Two Antidepressants?	25
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	25
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	24
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	24
Highlights From the Residents’ Journal: December 2024	24
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	24
Recommendations for the Usage of Ketamine and Esketamine	24
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	23
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg	23
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	23
Progress and Challenges in GxE Research on Depression	23
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	23
Time Course of Relapse Following Acute Treatment for Anorexia Nervosa	22
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	22
Functional Connectivity Mapping for rTMS Target Selection in Depression	22
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	22
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	22
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	22
Technology and Mental Health: State of the Art for Assessment and Treatment	21
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	21
Reports to the Membership	21
Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features	21
Behavior as Physiology: How Dynamical-Systems Theory Could Advance Psychiatry	21
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	21
Antidepressants and Bipolar Disorder: The Plot Thickens	20
Vaccines as Immunotherapies for Substance Use Disorders	20
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	20
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	20
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	20
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	20
Psychotropic Drug–Related Weight Gain and Its Treatment	19
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	19
Perinatal Mental Health: Advances and Opportunities	19
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	19
Polygenic Risk Scores and Genetics in Psychiatry	19
Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia	19
Neglect of Adverse Effects in Treatment Guidelines for Depression	18
Focusing on Substance Use Disorders, Opioids, and Craving	18
Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	18
Putting Genetics to Work in the Psychiatric Clinic	18
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	18
Highlights From the Residents’ Journal: September 2023	18

An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	18
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	17
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	17
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	17
Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	17
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	17
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	17
Understanding the Value and Limitations of MRI Neuroimaging in Psychiatry	17
The Risk of Overdose With Concomitant Use of Z-Drugs and Prescription Opioids: A Population-Based Cohort Study	17
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	17
Disclosure of Editors’ Financial Relationships	16
Increased Inflammation in Depression: A Little in All, or a Lot in a Few?	16
Reports to the Membership	16
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	16
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	16
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	16
New Insights Into Major Depression and the Treatment of Bipolar Depression	15
Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries	15
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	15
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	15
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	15
MDMA and MDMA-Assisted Therapy	15
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	15
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	15
Association Between Benzodiazepine or Z-Drug Prescriptions and Drug-Related Poisonings Among Patients Receiving Buprenorphine Maintenance: A Case-Crossover Analysis	15
Psychosis Risk With Prescription Amphetamine	15